title: Autoimmune Pitfalls of Anti-Tumor Necrosis Factor-Alpha Therapy.
authors.forename: Siniša
authors.initials: S
authors.lastname: Roginić
authors.forename: Alan
authors.initials: A
authors.lastname: Jelić
authors.forename: Asja
authors.initials: A
authors.lastname: Stipić-Marković
authors.forename: Artukovic
authors.initials: A
authors.lastname: Marinko
authors.forename: Irena N
authors.initials: IN
authors.lastname: Artuković
authors.forename: Martinović K
authors.initials: MK
authors.lastname: Dušanka
mesh_terms: D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D001323:Autoantibodies / Q000097:blood; D015551:Autoimmunity / Q000187:drug effects; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000009:adverse effects; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced / Q000175:diagnosis / Q000276:immunology / Q000503:physiopathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage*; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D028761:Withholding Treatment
chemical_list: D001323:Autoantibodies; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept; D011241:Prednisone